Phase 3 studies report functional cure in about 1 in 5 chronic hepatitis B patients treated with bepirovirsen
The facts
- Bepirovirsen is an experimental treatment for chronic hepatitis B that was evaluated in two phase 3 trials, B-Well 1 and B-Well 2.
- Results from the two studies were published in The New England Journal of Medicine and presented at the EASL meeting in Barcelona.
- Across the studies, about 1 in 5 patients treated with bepirovirsen achieved what researchers described as a functional cure for chronic hepatitis B.
- In pooled trial data, the functional cure rate was reported as 19% overall and 26% among patients with lower viral activity or lower baseline surface-antigen levels.
- The studies suggest some patients may be able to stop treatment and still keep the virus suppressed, offering a possible alternative to lifelong antiviral therapy.
- Chronic hepatitis B can cause serious liver disease, including cirrhosis, liver cancer, liver failure, and death.
- The drug did not produce a functional cure for most patients in the trials, leaving open how broadly it will change treatment if approved.
- GSK has sought regulatory approval for bepirovirsen in the United States, Japan, China, and Europe.
Context
What does a "functional cure" mean in this context?
In these reports, a functional cure means patients could stop treatment without showing signs of the hepatitis B virus because viral levels were reduced enough for the immune system to keep the infection in check Yahoo! Finance,U.S. News & World R….
Why is this development important for patients with chronic hepatitis B?
Chronic hepatitis B can persist for years and may lead to cirrhosis, liver cancer, or liver failure, while current care often involves lifelong antiviral medication; a treatment that allows some patients to stop therapy would change that for a subset of patients NYT,Yahoo! Finance,Yahoo! Finance.
What remains unresolved?
The treatment benefited only a minority of trial participants, so it is not a cure for most patients, and its future use still depends on regulatory decisions that GSK is seeking in multiple regions Yahoo! Finance,Straits Times.
Common ground, and where they split
- Common ground
- A finite treatment producing a functional cure in a meaningful minority of chronic hepatitis B patients marks a real advance, especially if some can stop therapy and keep the virus suppressed, even though most patients did not reach that outcome.
- Where Left and Right split
- Less a disagreement than a question of emphasis: a meaningful but limited gain because most patients were not cured, versus a credible path beyond lifelong antiviral therapy for the subset who may benefit.
How left and right read it
What stands out here is a meaningful breakthrough against a disease that can lead to cirrhosis, liver cancer, liver failure, and death. The phase 3 results suggest some patients may be able to stop treatment and still keep the virus suppressed, which matters because moving even a share of people off lifelong antiviral therapy could change what care looks like for those living with chronic hepatitis B.
The notable point is that an experimental treatment in phase 3 trials appears to offer a real alternative to lifelong antiviral therapy for some patients with chronic hepatitis B. But the studies also showed it did not produce a functional cure for most patients, so the key takeaway is promise with limits rather than a sweeping change in treatment.
The receipts — 51 sources
Wire services (12)
Other coverage (39)
A news briefing built to show both sides.
The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.